RemeGen Past Earnings Performance
Past criteria checks 0/6
RemeGen's earnings have been declining at an average annual rate of -26%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 27.2% per year.
Key information
-26.0%
Earnings growth rate
-9.8%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 27.2% |
| Return on equity | -49.9% |
| Net Margin | -123.4% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How RemeGen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,245 | -1,536 | 1,119 | 1,388 |
| 31 Dec 23 | 1,083 | -1,511 | 1,087 | 1,306 |
| 30 Sep 23 | 972 | -1,341 | 1,059 | 1,178 |
| 30 Jun 23 | 844 | -1,213 | 973 | 1,073 |
| 31 Mar 23 | 790 | -1,036 | 821 | 1,014 |
| 31 Dec 22 | 772 | -999 | 718 | 982 |
| 30 Sep 22 | 1,879 | 276 | 642 | 849 |
| 30 Jun 22 | 1,745 | 231 | 582 | 834 |
| 31 Mar 22 | 1,570 | 174 | 543 | 793 |
| 31 Dec 21 | 1,424 | 276 | 483 | 711 |
| 30 Sep 21 | 115 | -912 | 378 | 663 |
| 30 Jun 21 | 29 | -892 | 338 | 604 |
| 31 Mar 21 | 4 | -783 | 291 | 527 |
| 31 Dec 20 | 0 | -698 | 242 | 466 |
| 30 Sep 20 | 0 | -588 | 175 | 423 |
| 30 Jun 20 | 0 | -478 | 109 | 380 |
| 31 Mar 20 | 0 | -442 | 84 | 358 |
| 31 Dec 19 | 0 | -430 | 69 | 352 |
| 31 Dec 18 | 11 | -270 | 29 | 216 |
Quality Earnings: 9995 is currently unprofitable.
Growing Profit Margin: 9995 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 9995 is unprofitable, and losses have increased over the past 5 years at a rate of 26% per year.
Accelerating Growth: Unable to compare 9995's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 9995 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.1%).
Return on Equity
High ROE: 9995 has a negative Return on Equity (-49.91%), as it is currently unprofitable.